Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study.

Frontiers in pharmacology·2026
Same author

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Cancers·2026
Same author

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

Annals of hematology·2026
Same author

Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study.

American journal of hematology·2026
Same author

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

American journal of hematology·2026
Same author

Refractory Primary Immune Thrombocytopenia With Bleeding and Thrombosis: A Case Report.

The American journal of case reports·2026

Related Experiment Video

Updated: Jun 24, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

12.0K

Sepsis detection in hematologic and solid tumor malignancies using quantitative inflammatory biomarker differences in

Daniela Carcò1, Valeria Iachelli2, Uros Markovic3

  • 1Istituto Oncologico del Mediterraneo, Viagrande, Italy.

Scientific Reports
|August 28, 2025
PubMed
Summary

Sepsis diagnosis in cancer patients is challenging. Hematologic cancer patients show elevated biomarkers like IL-6, PCT, and MON for sepsis detection, unlike those with solid tumors, highlighting the need for tailored approaches.

Keywords:
Composite biomarker indexHematologic cancerSepsisSerum biomarkersSolid cancer

More Related Videos

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
05:28

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis

Published on: December 9, 2022

3.7K
A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

313

Related Experiment Videos

Last Updated: Jun 24, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

12.0K
Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
05:28

Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis

Published on: December 9, 2022

3.7K
A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

313

Area of Science:

  • Oncology
  • Infectious Diseases
  • Immunology

Background:

  • Sepsis, a life-threatening response to infection, poses a higher risk for cancer patients.
  • Blood cultures have limitations, especially in culture-negative sepsis, necessitating reliable serological biomarkers.
  • Distinguishing sepsis in malignancy patients requires understanding unique immune responses.

Purpose of the Study:

  • To evaluate the efficacy of serological biomarkers in diagnosing sepsis in patients with hematologic and solid tumors.
  • To compare the diagnostic performance of biomarkers between hematologic and solid cancer sepsis cases.
  • To identify cancer-specific diagnostic strategies for sepsis.

Main Methods:

  • Prospective observational study design.
  • Analysis of serological biomarkers including C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), white blood cells (WBC), lymphocytes (LYM), neutrophils (NEU), and monocytes (MON).
  • Evaluation of biomarker efficacy in distinguishing sepsis in patients with hematologic versus solid tumors.

Main Results:

  • Hematologic cancer patients with sepsis showed significantly elevated IL-6, PCT, and MON levels (AUC > 0.75).
  • Solid tumor patients with sepsis had a moderate, non-significant increase in PCT (AUC = 0.693).
  • Biomarker combinations improved diagnostic power for hematologic cancers but showed limited efficacy in solid tumors.

Conclusions:

  • IL-6, PCT, and MON are valuable biomarkers for sepsis detection in hematologic malignancies.
  • Current biomarkers have limited efficacy in diagnosing sepsis in solid tumors.
  • Cancer-specific diagnostic approaches are crucial, considering the distinct immune dynamics in hematologic versus solid tumors.